A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

This study has been completed.

First Received: March 3, 2003 Last Updated: October 20, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00055471

Purpose

The primary purpose of this study is to determine the safest dose of ZD4054 in men with prostate cancer

Condition	Intervention	Phase
Prostatic Neoplasms Metastases, Neoplasm	Drug: ZD4054	Phase II

Study Type:	Interventional
Study Design:	Treatment

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

Drug Information available for: ZD4054

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055471

Locations

United States, Ohio
Research Site
Cleveland, Ohio, United States, 44195
United States, Wisconsin
Research Site
Madison, Wisconsin, United States

Sponsors and Collaborators

AstraZeneca

More Information

Additional Information:

AstraZeneca Information Center This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	4054IL/0004
Study First Received:	March 3, 2003
Last Updated:	October 20, 2009
ClinicalTrials.gov Identifier:	NCT00055471 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

prostate cancer
Metastatic prostate cancer
bone metastases

Additional relevant MeSH terms:

Neoplastic Processes
Neoplasms
Neoplasms by Site
Pathologic Processes
Prostatic Diseases

Genital Neoplasms, Male
Neoplasm Metastasis
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on November 25, 2009